ライフサイエンスコーパス: CE-MS

1 CE-MS analysis was performed using a neutral capillary c

2 (CE-MS/MS)n is a practical technique since each CE-MS/MS

3 ntroduced to address the undersampling: (1) (CE-MS/MS)n using dynamic exclusion.

4 In addition, CE-MS was used to confirm major 8-aminopyrene-1,3,6-tris

5 , thereby expanding the capability of CE and CE-MS for profiling biomolecules.

6 bolite was found in common between LC-MS and CE-MS analysis as statistically significant.

7 for metabolite extraction across UPLC-MS and CE-MS platforms accommodating different columns and ioni

8 he interface can be used for both nLC-MS and CE-MS.

9 ttranslational modifications using CE-MS and CE-MS/MS is demonstrated using this method with < 10 fmo

10 ary analytical techniques (LC-MS, GC/MS, and CE-MS) with regards to analytical method optimization (s

11 ibe the application of a microfluidics-based CE-MS system for analysis of released glycans, glycopept

12 e fractionated using RP-HPLC and analyzed by CE-MS yielding a total of 28538 quantified peptides that

13 of the APTS-labeled glycans was confirmed by CE-MS.

14 rs in fish serum glycans are investigated by CE-MS/MS.

15 be identified also in their native state by CE-MS without derivatization.

16 Based on these characteristics, (CE-MS/MS)n can be performed in which multiple CE-MS/MS s

17 Compared to the classical CE-MS approaches, the integration of t-ITP combined with

18 rophoresis with mass spectrometry detection (CE-MS) to assess hemoglobin glycation in whole blood lys

19 -MS/MS subanalysis consumes <10 nL, and each CE-MS/MS subanalysis takes approximately 10 min; therefo

20 mental variables are manipulated during each CE-MS/MS subanalysis in order to maximize sequence cover

21 ge (every approximately 100 m/z) during each CE-MS/MS subanalysis without using dynamic exclusion.

22 -MS/MS)n is a practical technique since each CE-MS/MS subanalysis consumes <10 nL, and each CE-MS/MS

23 nd equal sample concentration conditions for CE-MS while providing complementary data to LC-MS, demon

24 ates that recent improvements in interfacing CE-MS coupling, leading to a considerably improved sensi

25 To evaluate the system, LC-MS and LC-CE-MS analyses of protein digests were performed and com

26 ass spectrometer for comprehensive online LC-CE-MS of proteolytic digests.

27 The same LC-CE-MS method was also used to characterize the N-linked

28 otal site occupancy were quantified using LC-CE-MS data.

29 considerable improvement over sheath-liquid CE-MS.

30 ures were found with classical sheath-liquid CE-MS.

31 y electrophoresis-mass spectrometry methods (CE-MS) for glycomics and glycoproteomics is limited by t

32 he device has been used to perform microchip CE-MS analysis of peptides and proteins with efficiencie

33 he ADC was analyzed using the same microchip CE-MS method.

34 distribution generated from the microfluidic CE-MS data compared favorably to results from infusion-E

35 beta-Hb was calculated from the microfluidic CE-MS data using peak areas generated from extracted ion

36 samples were analyzed using the microfluidic CE-MS method and a clinically used immunoassay to measur

37 ented here demonstrate that the microfluidic CE-MS method is capable of rapidly assessing Hb and HSA

38 In this work, multisegment injection (MSI)-CE-MS was used as multiplexed separation platform for hi

39 MSI-CE-MS offers an unprecedented approach to enhance sample

40 that demonstrated good agreement between MSI-CE-MS and validated FIA-MS/MS methods within an accredit

41 in human urine were reliably measured by MSI-CE-MS via serial injection of seven urine samples within

42 lly, nontargeted metabolite profiling by MSI-CE-MS with temporal signal pattern recognition revealed

43 llary electrophoresis-mass spectrometry (MSI-CE-MS) as a multiplexed separation platform for metabolo

44 llary electrophoresis-mass spectrometry (MSI-CE-MS) was developed to provide comparable sample throug

45 llary electrophoresis-mass spectrometry (MSI-CE-MS).

46 We demonstrate that MSI-CE-MS enables serial injections of 10 samples within a s

47 E-MS/MS)n can be performed in which multiple CE-MS/MS subanalyses (injections followed by analyses) a

48 Testing of this novel CE-MS system showed its ability to characterize proteomi

49 utilizes the most significant advantages of CE-MS/MS, including economy of sample size, fast analysi

50 This paper describes the development of CE-MS technology with on-line LIF detection that allows

51 This work demonstrates the potential of CE-MS to provide a comprehensive glycosylation profile w

52 or this is a reported lack of sensitivity of CE-MS when compared to gas chromatography-mass spectrome

53 these advantages, the long-term stability of CE-MS remains a major obstacle hampering its widespread

54 eful optimization and rigorous validation of CE-MS protocols are crucial for developing a rapid, low

55 g multivariate statistical analysis based on CE-MS metabolomics of CSF samples was obtained using 73

56 eloped using large-scale bottom-up proteomic CE-MS data (5% ( approximately 0.8M) acetic acid as back

57 In this technique, several CE-MS/MS analyses (injection followed by separation) wer

58 valuated with both sheathless and sheathflow CE-MS ion sources.

59 s were detected in human urine by sheathless CE-MS whereas about 300 molecular features were found wi

60 Hence, sheathless CE-MS can be used for in-depth metabolic profiling of bi

61 ary preconcentration procedure in sheathless CE-MS further resulted in subnanomolar limits of detecti

62 Under optimal conditions, the sheathless CE-MS interface provided significantly increased ionizat

63 e were used for evaluation of the sheathless CE-MS platform.

64 The sheathless CE-MS system also proved highly suitable for the glycopr

65 ion using a true zero dead-volume sheathless CE-MS interface.

66 Capillary electrophoresis-mass spectrometry (CE-MS) and whole-genome gene expression arrays, aided by

67 capillary electrophoresis-mass spectrometry (CE-MS) in an integrated microfluidic platform to analyze

68 capillary electrophoresis-mass spectrometry (CE-MS) interface and both LTQ-XL and LTQ-Orbitrap-Velos

69 capillary electrophoresis-mass spectrometry (CE-MS) is developed to examine metabolic differences in

70 Capillary electrophoresis-mass spectrometry (CE-MS) is still widely regarded as an emerging tool in t

71 Capillary electrophoresis-mass spectrometry (CE-MS) represents a high efficiency microscale separatio

72 ion of a robust online CE-mass spectrometry (CE-MS) system used for the characterization of several C

73 capillary electrophoresis mass spectrometry (CE-MS) technique is introduced for age estimation of sil

74 capillary electrophoresis-mass spectrometry (CE-MS) technology was developed to identify minor glycan

75 llary electrophoresis and mass spectrometry (CE-MS) to develop a method for simultaneous profiling bo

76 capillary electrophoresis-mass spectrometry (CE-MS), and nuclear magnetic resonace (NMR).

77 capillary electrophoresis-mass spectrometry (CE-MS), using a porous tip sprayer, is proposed for the

78 lectrophoresis coupled to mass spectrometry (CE-MS).

79 ry electrophoresis-tandem mass spectrometry (CE-MS/MS) method for the determination of halosulfuron-m

80 ry electrophoresis-tandem mass spectrometry (CE-MS/MS) method was developed for enantiomeric quantifi

81 ry electrophoresis-tandem mass spectrometry (CE-MS/MS) of tryptic digests is described.

82 ry electrophoresis-tandem mass spectrometry (CE-MS/MS) procedure which employs a high sensitivity por

83 For each study, CE-MS was able to successfully identify components seen

84 e coverage, we introduce a novel technique, (CE-MS/MS)n, which utilizes the most significant advantag

85 In this technique, (CE-MS/MS)n is performed by scanning a narrow mass range

86 Moreover, we were able to demonstrate that CE-MS is a powerful method for the identification of low

87 Our results suggest that CE-MS metabolomics of CSF samples can be a useful tool t

88 The CE-MS analysis takes ~20 min, consumes only nanoliters o

89 The CE-MS based method eliminates the need to label the N-gl

90 Because the CE-MS and expression profiling are both amenable to smal

91 ntifying 1371 phosphopeptides present in the CE-MS data set and found 49 phosphopeptides to be differ

92 evaluated to optimize the performance of the CE-MS system, resulting in a mass limit of detection of

93 Overall, the CE-MS method described here enables rapid setup and anal

94 erefore, does not add any dead volume to the CE-MS or nLC-MS interface.

95 of cytoplasm for metabolomic analysis using CE-MS.

96 everal posttranslational modifications using CE-MS and CE-MS/MS is demonstrated using this method wit

97 s approach that combines SILAC labeling with CE-MS analysis.